Anti-CD5 Antibody Composition for Blocking Tumor Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent checkpoint inhibitors to activate T cells and B cells and elicit anti-cancer immune responses in patients with cancer, as CD5 activation leads to immune suppression.
Innovation Solution
Development of an anti-CD5 antibody comprising specific CDR sequences (SEQ ID NOs:1-6) and a recombinant protein with a transmembrane domain, combined with a PD-1 inhibitor, to enhance immune activation against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD5 activation is utilized for immune response, then T cell and B cell activation is improved, but immune suppression increases
Solution Approach 1:
The patent converts the harmful immune suppression effect of CD5 activation into a beneficial anti-tumor immune response. By designing an anti-CD5 antibody that blocks CD5 signaling pathways, the invention prevents CD5-mediated immune suppression while preserving or enhancing anti-tumor immunity. The antibody transforms the harmful role of CD5 in tumor progression into a therapeutic opportunity by inhibiting its suppressive functions.
2Reliability
If potent checkpoint inhibitors are used to activate T cells, then anti-cancer immune response is improved, but immune suppression by CD5 persists
Solution Approach 1:
The patent merges the mechanisms of checkpoint inhibition with CD5 blockade into a single therapeutic agent. The anti-CD5 antibody combines the functions of traditional checkpoint inhibitors (activating T cells) with CD5 signaling inhibition (overcoming CD5-mediated suppression). This unified approach addresses both aspects of immune regulation simultaneously, providing synergistic anti-tumor activity.
3Ease of manufacture
If conventional antibody structures are used, then manufacturing is simplified, but binding affinity and specificity to CD5 are insufficient
Solution Approach 1:
The patent optimizes the antibody structure by modifying key parameters including the variable region sequences, CDR regions, and framework regions to enhance binding affinity and specificity for CD5. The invention uses precisely defined amino acid sequences in the variable domains that are engineered to maximize complementarity to the CD5 antigen while maintaining manufacturability through conventional antibody formats.
Data Source
AI summary
Provided herein are, inter alia, antibodies (e.g., humanized antibodies, monoclonal antibodies) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies) that are capable of binding CD5. The antibodies and antibody compositions provided herein include novel light and heavy chain domain CDRs and framework regions, and bind CD5 with high efficiency and specificity, thereby effectively targeting CD5 expressing cells. The antibodies provided herein may form part of recombinant proteins also referred to herein as antibody compositions (e.g., chimeric antigen receptors or bispecific antibodies) to be used, inter alia, for therapeutic cancer applications.